Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zevra Therapeutics, Inc. (ZVRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, Zevra uses current reports on Form 8-K and other periodic filings to communicate material events, financial results, and governance changes related to its rare disease business.
Investors can review Form 8-K filings in which Zevra reports quarterly financial results and corporate updates, including revenue from its commercial products for Niemann-Pick disease type C and certain urea cycle disorders, operating expenses, and information about conference calls and webcasts. Other 8-K filings detail matters such as the resignation and transition of key officers, appointment of interim financial leadership, and board-level changes, along with summaries of related agreements and compensation terms.
These filings also document equity inducement awards granted under Zevra’s employment inducement award plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing transparency into stock option grants to new employees. Together with annual and quarterly reports (when available), the filings offer a structured view of Zevra’s financial condition, capital structure, and risk disclosures as it advances therapies like MIPLYFFA and OLPRUVA and develops candidates such as celiprolol.
On Stock Titan, SEC documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR help users see new Zevra filings as they appear, while specialized views of Forms 3, 4, and 5 make it easier to track insider transactions. For long-form reports such as 10-K and 10-Q, AI-generated highlights can help users quickly identify important sections on revenue drivers, research and development spending, and material risks related to Zevra’s rare disease portfolio.
Zevra Therapeutics (ZVRA) reported sharply improved results in its Q3 2025 10-Q. Revenue rose to $26.1 million from $3.7 million a year ago, driven mainly by MIPLYFFA sales. The company posted a small net loss of $0.5 million for the quarter versus a $33.2 million loss last year.
For the nine months ended September 30, 2025, revenue reached $72.3 million, and net income was $71.1 million, aided by a $148.3 million gain from selling a priority review voucher. Results also reflect a $58.7 million intangible asset impairment and $11.7 million in inventory write-downs. MIPLYFFA generated $22.4 million in Q3 and $61.0 million year-to-date; OLPRUVA contributed $0.1 million in Q3 and $0.5 million year-to-date. The AZSTARYS license produced $1.2 million in Q3.
Liquidity strengthened: cash and cash equivalents were $54.4 million with $175.9 million in investment securities at fair value, and stockholders’ equity increased to $133.2 million. Long-term debt stood at $61.3 million under the 2024 term loan facility. As of November 3, 2025, 56,297,535 shares of common stock were outstanding.
Zevra Therapeutics (ZVRA) reported it has furnished a press release announcing financial results and corporate updates for the third quarter ended September 30, 2025. The company also scheduled a conference call and audio webcast for November 5, 2025 at 4:30 p.m. ET to discuss these updates.
The press release is furnished as Exhibit 99.1 and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly specified.
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (ZVRA), reported equity transactions on
ZEVRA THERAPEUTICS, INC. (ZVRA) filed a Form 144 disclosing a proposed sale of 19,500 common shares by an insider through Morgan Stanley Smith Barney LLC on
The securities were acquired as Restricted Stock Units and the acquisition and planned sale date are both reported as
Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.
Alvin Shih, a director of Zevra Therapeutics (ZVRA), purchased 20,000 shares of the company's common stock on 09/12/2025 at a weighted-average price of $7.89 per share. The Form 4 shows the transaction was reported as an acquisition and that the reporting person beneficially owns 20,000 shares following the purchase. The footnote states the $7.89 figure is a weighted average from multiple trades priced between $7.85 and $7.90 and that detailed allocation of trades is available on request. The filing was signed by an attorney-in-fact on behalf of Mr. Shih.
Zevra Therapeutics director John B. Bode acquired 5,000 shares of the company's common stock on 08/19/2025 at a reported price of $9.165 per share. After the purchase he beneficially owns 45,000 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/20/2025.
Zevra Therapeutics reported a net income of $74.7 million for the quarter ended June 30, 2025, driven largely by a $148.3 million gain on the sale of a transferable priority review voucher (PRV). Product revenue rose to $25.9 million for the quarter and $46.3 million year-to-date, led by MIPLYFFA sales of $21.5 million in the quarter.
The balance sheet strengthened with $47.7 million in cash and approximately $170.0 million in fair-value securities, bringing total assets to $256.3 million and stockholders' equity to $117.2 million. Material charges included a $58.7 million intangible-asset impairment related to OLPRUVA and an $11.7 million inventory write-down. Long-term debt was $60.7 million. The company disclosed ongoing litigation concerning the AZSTARYS license agreement.
Zevra Therapeutics announced it issued a press release on August 12, 2025 reporting financial results and corporate updates for the quarter ended June 30, 2025. The company scheduled a conference call and audio webcast for Tuesday, August 12, 2025 at 4:30 p.m. ET to discuss those results. The press release is furnished as Exhibit 99.1 to this Form 8-K and is explicitly furnished, not filed, so it is not incorporated by reference into Zevra's other securities filings. The Form 8-K does not include financial statements or tables within the filing itself.